Astellas Pharma, Inc.

Contract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet

Royalty Pharma has built a unique and valuable business model within the biopharma sector, buying royalty revenue streams in exchange for capital to finance drug development and commercialization. And

Pfizer has thrust into the global race for a best-in-class bispecific antibody that inhibits both programmed cell death protein 1/ligand 1 (PD-1/L1) and vascular endothelial growth factor (VEGF) as it

A clinical trial analysis designed around biomarker subgroups in Pfizer ‘s application to expand the first-line prostate cancer indication for its PARP inhibitor Talzenna (talazoparib) to all-comers